I2O THERAPEUTICS, INC.
8Patents
8Active
8Granted
58Portfolio score
Filing activity: Oct 10, 2019 → Feb 16, 2024
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US12233111B2 | Compositions comprising pharmaceutically acceptable salts of glucagon-like peptide-1 analogs and uses thereof | Chemistry; Metallurgy | 2 | Active |
| US12122816B2 | Long acting peptide tyrosine tyrosine (PYY) analogs and methods of use | Human Necessities | 0 | Active |
| US12018059B2 | Human amylin analog polypeptides and methods of use | Human Necessities | 0 | Active |
| US12042557B2 | Rapid establishment and/or termination of substantial steady-state drug delivery | Human Necessities | 0 | Active |
| US12084485B2 | Long acting glucagon like polypeptide-1 (GLP-1) receptor agonists and methods of use | Human Necessities | 0 | Active |
| US12337029B2 | Compositions comprising pharmaceutically acceptable salts of amylin analogs and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US11840559B2 | Glucagon-receptor selective polypeptides and methods of use thereof | Human Necessities | 0 | Active |
| US12350320B2 | Compositions comprising pharmaceutically acceptable salts of glucagon-like peptide-1 analogs and pharmaceutically acceptable salts of amylin analogs, and uses thereof | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.